AsiaNet-Pakistan Premier Editorial Content and Press Release Distribution Service
Karachi: AGP has reported a solid financial performance with a 15% year-on-year increase in topline growth for the first nine months of calendar year 2025, driven by strategic price adjustments and resilient volume growth. This trend is expected to continue into the fourth quarter, culminating in a projected 17% revenue growth for the full year.
The company’s management highlighted in a recent briefing that the price hikes were implemented in alignment with Consumer Price Index adjustments, ensuring competitiveness while maintaining volume. AGP’s year-to-date volumetric growth stands at 3.9%, in contrast to the industry’s overall decline of 0.1%.
AGP has a significant export presence in Afghanistan, having met its export targets for 2025. However, potential trade suspensions could affect exports in 2026 as the company seeks to expand its export markets over the next two years.
The company’s stock is considered a strong contender within the pharmaceutical sector, with current valuations reflecting a forward price-to-earnings ratio of 10.8. Analysts have set a target price of Rs260 per share by December 2026, indicating a potential upside of 42% year-on-year.